Associations - NOTCH1 (Notch 1)

NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
NOTCH1 mutation	Non Small Cell Lung Cancer	NOTCH1 mutation	Non Small Cell Lung Cancer	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ibrutinib + rituximab + obinutuzumab Resistant: B - Late Trials ibrutinib + rituximab + obinutuzumab Resistant : B	ibrutinib + rituximab + obinutuzumab Resistant: B - Late Trials ibrutinib + rituximab + obinutuzumab Resistant : B
EGFR mutation + NOTCH1 mutation	Non Small Cell Lung Cancer	EGFR mutation + NOTCH1 mutation	Non Small Cell Lung Cancer	gefitinib Resistant: B - Late Trials gefitinib Resistant : B	gefitinib Resistant: B - Late Trials gefitinib Resistant : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: B - Late Trials venetoclax + ibrutinib Sensitive : B	venetoclax + ibrutinib Sensitive: B - Late Trials venetoclax + ibrutinib Sensitive : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
NOTCH1 mutation	Non Small Cell Lung Cancer	NOTCH1 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
NOTCH1 mutation + TMB-L + MSI-L/dMMR	Bladder Cancer	NOTCH1 mutation + TMB-L + MSI-L/dMMR	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
NOTCH1 mutation + MSI-L/dMMR	Bladder Cancer	NOTCH1 mutation + MSI-L/dMMR	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3

NOTCH1 (Notch 1)

Associations(54)

Associations
(54)